Macular Edema (Ophthalmology) - Drugs in Development, 2021

November 2021 | 102 pages | ID: M2A137A3A5AFEN
Global Markets Direct

Abstracts

Macular Edema (Ophthalmology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Drugs In Development, 2021, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 4, 2, 3, 9 and 1 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Macular Edema - Therapeutics Assessment
Macular Edema - Companies Involved in Therapeutics Development
Macular Edema - Drug Profiles
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Macular Edema, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Macular Edema - Pipeline by 3SBio Inc, 2021
Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, 2021
Macular Edema - Pipeline by Anew Oncology Inc, 2021
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, 2021
Macular Edema - Pipeline by Celon Pharma SA, 2021
Macular Edema - Pipeline by Clearside BioMedical Inc, 2021
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Macular Edema - Pipeline by Huadong Medicine Co Ltd, 2021
Macular Edema - Pipeline by Luye Pharma Group Ltd, 2021
Macular Edema - Pipeline by Mabion SA, 2021
Macular Edema - Pipeline by Novartis AG, 2021
Macular Edema - Pipeline by PharmAbcine Inc, 2021
Macular Edema - Pipeline by Polus Inc, 2021
Macular Edema - Pipeline by Prestige BioPharma Ltd, 2021
Macular Edema - Pipeline by Profarma, 2021
Macular Edema - Pipeline by Sustained Nano Systems LLC, 2021
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, 2021
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, 2021
Macular Edema - Pipeline by Tarsius Pharma Ltd, 2021
Macular Edema - Pipeline by Tiantai Yinkang Biological Medicine Co Ltd, 2021
Macular Edema - Pipeline by Xbrane Biopharma AB, 2021
Macular Edema - Dormant Projects, 2021
Macular Edema - Dormant Projects, 2021 (Contd..1)
Macular Edema - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Macular Edema, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021